Induced luteal regression in the primate: evidence for apoptosis and changes in c-myc protein.
There is increasing molecular evidence that apoptosis is involved in the process of structural luteal regression in non-primate species. Apoptosis is dependent upon the activation of certain proto-oncogenes and c-myc protein has an important regulatory role in this process in some cell types. The aim of the present study was to determine the occurrence and localisation of c-myc protein within the primate corpus luteum, determine changes during induction of luteal regression and examine the corpora lutea for morphological evidence of apoptosis. Ovaries were studied from marmoset monkeys in the late follicular, and in the early, mid and late luteal phases. Luteal regression was induced either by treatment with prostaglandin F2 alpha analogue or GnRH antagonist administered during the mid luteal phase and ovaries obtained 24 and 48 h later. Immunocytochemistry was performed using a monoclonal antibody to the c-myc protein. In pre-ovulatory follicles positive staining was found in the nucleus of a few granulosal cells and in the cytoplasm of thecal cells. c-myc was present in all corpora lutea where it was localised predominantly in the cytoplasm. In early corpora lutea, scattered cells with intense staining were observed in the presence of a majority of moderately or weakly stained cells. In the mid and late luteal phases, corpora lutea were uniformly moderately stained for c-myc. Following induction of luteal regression, regression, nuclear degeneration with condensation and fragmentation indicative of apoptosis was observed. In other luteal cells, increased membranes suggested necrosis.(ABSTRACT TRUNCATED AT 250 WORDS)
D000818:Animals; D017209:Apoptosis; D002144:Callithrix / Q000502:physiology*; D002467:Cell Nucleus / Q000378:metabolism; D003008:Cloprostenol / Q000494:pharmacology; D003338:Corpus Luteum / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D003593:Cytoplasm / Q000378:metabolism; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006727:Hormone Antagonists / Q000494:pharmacology; D007150:Immunohistochemistry; D008183:Luteal Phase; D003341:Luteolysis / Q000502:physiology*; D009336:Necrosis; D009842:Oligopeptides / Q000494:pharmacology; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism*
D006727:Hormone Antagonists; D009842:Oligopeptides; D016271:Proto-Oncogene Proteins c-myc; D007987:Gonadotropin-Releasing Hormone; D003008:Cloprostenol; C084350:antarelix